# Cellumen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellumen

- Industry: Pharmaceuticals
- Headquarters: Pittsburgh, US
- Website: www.cellumen.com
- Total disclosed funding: $9.5M
- Latest round: Series B (Feb 18, 2009)
- Investors on record: 3

## About

Based in Pennsylvania, US, and founded in 2004 by CEO Lansing Taylor, Cellumen, Inc. provides a cellular systems biology solution that provides accurate predictions of drug efficacy and safety. In August 2010, Cellumen was acquired by Apredica (Cyprotex).

The company's flagship offering, CellCiphr, includes a suite of advanced reagents and assays designed to measure and manipulate cell function. The products are used for profiling cellular models of disease and toxicity, enabling better lead generation, the identification of toxic liabilities early in the discovery process, and improved patient stratification.

## Funding rounds

- Series B, Feb 18, 2009, $0.5M — Pittsburgh Life Sciences Greenhouse
- Series B, Jul 10, 2007, $8.7M — Novitas Capital, Safeguard Scientifics
- Series A, Aug 9, 2006, $0.3M — Novitas Capital

## Investors

- Novitas Capital (https://capitalatlas.ai/funds/novitas-capital) — Series A, Series B
- Safeguard Scientifics (https://capitalatlas.ai/funds/safeguard-scientifics) — Series B
- Pittsburgh Life Sciences Greenhouse (https://capitalatlas.ai/funds/pittsburgh-life-sciences-greenhouse) — Series B